Skip to main content
Emcure Pharmaceuticals Limited logo

Emcure Pharmaceuticals Limited — Investor Relations & Filings

Ticker · EMCURE ISIN · INE168P01015 LEI · 335800WYB6OIBY9EOZ42 BSE.NS Manufacturing
Open in API
Filings indexed 201 across all filing types
Latest filing 2025-06-12 Share Issue/Capital Cha…
Country IN India
Listing BSE.NS EMCURE

About Emcure Pharmaceuticals Limited

https://www.emcure.com

Emcure Pharmaceuticals Limited is a research-driven global pharmaceutical organization engaged in the development, manufacturing, and marketing of a broad range of differentiated pharmaceutical products. The company maintains a diverse portfolio across several key therapeutic areas, including gynaecology, cardiovascular, oncology, anti-infectives, and HIV/AIDS. With a strong emphasis on research and development, Emcure operates multiple state-of-the-art manufacturing facilities and R&D centers globally. Its business model focuses on complex generics and innovative formulations, serving healthcare needs in over 70 countries. The company is recognized for its vertically integrated operations and commitment to high-quality standards, catering to both regulated and emerging markets worldwide.

Recent filings

Filing Released Lang Actions
Allotment of Securities
Share Issue/Capital Change Classification · 100% confidence The document is an official communication addressed to stock exchanges regarding the allotment of equity shares pursuant to the exercise of Employee Stock Option Scheme (ESOP). It details the increase in issued and paid-up share capital due to the allotment of shares. The subject and content clearly indicate it is about a capital change event related to share allotment. The document is short (2358 characters) and is an announcement of a share capital change, not a full financial report or detailed filing. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2025-06-12 English
Cessation
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges regarding the resignation of a senior management personnel, Mr. Anil Kothiyal, from Emcure Pharmaceuticals Limited. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosures about changes in senior management. The content includes details about the resignation date and reason but does not contain financial data, earnings, or report content. The document is short (3190 characters) and serves as an announcement of a management change rather than a financial report or other filing type. Therefore, it fits the category of Board/Management Information (MANG).
2025-06-03 English
Acquisition
M&A Activity Classification · 95% confidence The document is an official communication from Emcure Pharmaceuticals Limited to stock exchanges (NSE and BSE) regarding an acquisition under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. It provides detailed disclosure about the acquisition of shares in Torrent Urja 37 Private Limited, including the nature of the transaction, shareholding percentage, consideration, and background of the target entity. The document is a regulatory announcement about a corporate transaction (acquisition) and does not contain financial statements or detailed financial performance data. It is not a full annual or interim report, nor an earnings release or audit report. The content fits the category of M&A Activity announcements as it relates to a share subscription and shareholders' agreement and acquisition details. Therefore, the appropriate classification is M&A Activity (TAR). The document length (6500 characters) and content support this classification with high confidence.
2025-06-02 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings conference call for Emcure Pharmaceuticals Limited for the fourth quarter and full fiscal year 2025. It includes management commentary on financial results, business performance, strategic initiatives, and outlook. The text references the earnings call date, mentions the release of financials, and contains a Q&A style format typical of call transcripts. It is not a brief announcement, regulatory filing, or a report publication notice, but the full transcript of the earnings call. Therefore, the appropriate classification is Call Transcript (CT).
2025-05-28 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the newspaper publication of the company's audited financial results for the quarter and year ended March 31, 2025. It references Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and mentions that extracts of the audited financial results have been published in newspapers and uploaded on the company's website. The document itself does not contain the full financial results or detailed financial statements but is an announcement about the publication of these results. The document length is short (1901 characters), and it serves as a notification rather than the full report. According to the 'Menu vs Meal' rule, this is an announcement of a report publication rather than the report itself. Therefore, the appropriate classification is Report Publication Announcement (RPA).
2025-05-23 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a short notice from Emcure Pharmaceuticals Limited addressed to stock exchanges, informing about the availability of the audio recording of the Q4 FY25 earnings call on their website. It references Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provides a link to the audio file. The document does not contain the transcript or detailed financial data but only announces the availability of the earnings call recording. According to the classification rules, such announcements about earnings call recordings are best classified as Call Transcript (CT) related documents, since the content is about the earnings call audio recording. However, since the actual transcript is not included, and only the audio recording availability is announced, this is closest to a Call Transcript (CT) category as it pertains directly to the earnings call content. Confidence is high due to explicit mention of earnings call and audio recording.
2025-05-22 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.